KEGG   DRUG: Ibritumomab tiuxetan
Entry
D04489                      Drug                                   
Name
Ibritumomab tiuxetan (USAN/INN);
Ibritumomab tiuxetan (genetical recombination) (JAN);
Zevalin (TN)
Product
ZEVALIN (Acrotech Biopharma)
Remark
Therapeutic category: 4291 4300
ATC code: V10XX02
Product: D04489<JP/US>
Efficacy
Antineoplastic, Radioactive agent, Anti-CD20 antibody
  Disease
Low-grade or follicular non-Hodgkin's lymphoma (CD20-directed) [DS:H00005 H00011 H01613]
  Type
Monoclonal antibody
Target
CD20 [HSA:931] [KO:K06466]
  Pathway
hsa04640  Hematopoietic cell lineage
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 V VARIOUS
  V10 THERAPEUTIC RADIOPHARMACEUTICALS
   V10X OTHER THERAPEUTIC RADIOPHARMACEUTICALS
    V10XX Various therapeutic radiopharmaceuticals
     V10XX02 Ibritumomab tiuxetan (90Y)
      D04489  Ibritumomab tiuxetan (USAN/INN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D04489  Ibritumomab tiuxetan (USAN/INN); Ibritumomab tiuxetan (genetical recombination) (JAN)
  43  Radioactive drugs
   430  Radioactive drugs
    4300  Radioactive drugs
     D04489  Ibritumomab tiuxetan (USAN/INN); Ibritumomab tiuxetan (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   CD molecules
    CD20
     D04489  Ibritumomab tiuxetan (USAN/INN) <JP/US>
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D04489
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D04489
Other DBs
CAS: 206181-63-7
PubChem: 47206337
NIKKAJI: J2.115.705H
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system